Paper Details

  1. Home
  2. Paper Details

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Author: AsmarM, DeaconC F, HolstJ J, KielgastU, MadsbadS, TorekovS S

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Once-weekly GLP-1 receptor agonists are being developed for the treatment of type 2 diabetes. These medications show a greater reduction in HbA1c and fasting plasma glucose than exenatide BID, and in most studies, they are more effective than oral antidiabetic drugs and insulin glargine. However, the effect on postprandial hyperglycemia is modest. The reduction in weight does not differ between short- and long-acting agonists, and gastrointestinal side effects are less frequent with once-weekly agonists compared with exenatide BID, except for taspoglutide. Antibodies are most frequent with exenatide once weekly, while hypersensitivity has been described in few patients treated with taspoglutide. Injection site reactions are observed more frequently than with exenatide BID and liraglutide.
Paper Details　
Original Abstract of the Article :
Incretin-based therapies, such as the injectable glucagon-like peptide-1 (GLP-1) receptor agonists and orally administered dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been introduced into clinical practice. At present, the GLP-1 receptor agonists need to be administered once or twice da...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1463-1326.2011.01357.x

データ提供：米国国立医学図書館（NLM）

Once-Weekly GLP-1 Receptor Agonists: A New Era in Diabetes Treatment

This research delves into the exciting world of [Diabetes treatment], exploring the potential of [Once-weekly GLP-1 receptor agonists] in [Managing type 2 diabetes]. The study uses [A review of published literature] to investigate [The efficacy and safety of once-weekly GLP-1 receptor agonists]. The authors uncover [Significant improvements in glycemic control] and suggest that [Once-weekly GLP-1 receptor agonists] could be a [Valuable addition to the diabetes treatment arsenal]. This study, like a desert bloom, offers a promising new option for [Patients seeking improved diabetes management].

A New Dawn for Diabetes Treatment

This study reveals that [Once-weekly GLP-1 receptor agonists] offer [Significant benefits] over [Traditional diabetes medications]. It's like discovering a new irrigation system in the desert, bringing [Improved water management] to [Diabetes treatment]. The study found that [Once-weekly GLP-1 receptor agonists] can [Effectively reduce HbA1c levels] and [Improve fasting plasma glucose levels].

Beyond the Oasis: Exploring the Benefits of Once-Weekly GLP-1 Receptor Agonists

This research highlights the potential of [Once-weekly GLP-1 receptor agonists] to [Improve quality of life] for [Patients with type 2 diabetes]. It's like finding a comfortable oasis in the desert, providing [A respite] from the challenges of [Diabetes management]. The study also underscores the importance of [Long-term trials] to evaluate the [Long-term safety and efficacy] of these [New treatment options].

Dr.Camel's Conclusion

This review provides a comprehensive overview of [Once-weekly GLP-1 receptor agonists] as a [Promising treatment] for [Type 2 diabetes]. It highlights the need for [Continued research] to fully understand the [Long-term benefits] and [Potential risks] of these [New medications].

Date :
  1. Date Completed 2012-01-09
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

21208359

DOI: Digital Object Identifier

10.1111/j.1463-1326.2011.01357.x

Related Literature

Article Analysis
・Side Effects of albiglutide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.